Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y3L5
UPID:
RAP2C_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y3L5; B3KWD6; Q5H9H9; Q9BTS0
Background:
Ras-related protein Rap-2c is a pivotal small GTP-binding protein, oscillating between GDP-bound inactive and GTP-bound active states. It is instrumental in cytoskeletal rearrangements and cell spreading, primarily through the activation of TNIK. Additionally, it contributes to SRE-mediated gene transcription, highlighting its versatile role in cellular processes.
Therapeutic significance:
Understanding the role of Ras-related protein Rap-2c could open doors to potential therapeutic strategies.